Multi OIT to Test Immune Markers After Minimum Maintenance Dose
Status:
Completed
Trial end date:
2019-01-30
Target enrollment:
Participant gender:
Summary
Few studies have been conducted to optimize safety of multiple food allergen oral
immunotherapy (OIT) in conjunction with Omalizumab as well as to identify the immunological
mechanism(s) underlying any long-lasting effects of OIT. To address these issues in the field
of food allergy research, we have designed this study to test whether: 1) Omalizumab improves
the safety of multiple food allergen OIT in subjects with multi food allergies, 2) Omalizumab
treatment with multiple food allergen OIT is associated with the ability to use a lower
maintenance dose of each food allergens in the OIT regimen, particularly in younger subjects
with food allergies.
Phase:
Phase 2
Details
Lead Sponsor:
Kari Christine Nadeau Kari Christine Nadeau, MD PhD